The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 15, 2015
Filed:
Aug. 27, 2013
Applicant:
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Inventor:
Robert P. Ricciardi, East Marlborough, PA (US);
Assignee:
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/65 (2006.01); A61K 31/095 (2006.01); A61K 31/166 (2006.01); A61K 31/198 (2006.01); A61K 31/426 (2006.01); A61K 31/10 (2006.01); A61K 31/341 (2006.01); A61K 31/351 (2006.01); A61K 31/352 (2006.01); A61K 31/357 (2006.01); A61K 31/42 (2006.01); A61K 31/427 (2006.01); A61K 31/429 (2006.01); A61K 31/473 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01);
U.S. Cl.
CPC ...
A61K 31/65 (2013.01); A61K 31/095 (2013.01); A61K 31/10 (2013.01); A61K 31/166 (2013.01); A61K 31/198 (2013.01); A61K 31/341 (2013.01); A61K 31/351 (2013.01); A61K 31/352 (2013.01); A61K 31/357 (2013.01); A61K 31/42 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/429 (2013.01); A61K 31/473 (2013.01); A61K 31/496 (2013.01); A61K 31/519 (2013.01);
Abstract
This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.